Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)
A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) Compared To A 23-Valent Pneumococcal Polysaccharide (23vPS) Vaccine in Ambulatory Elderly Individuals Aged 70 Years And Older Who Received One Dose of 23vPS At Least 5 Years Prior To Study Enrollment
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Arlov, Sweden, 23234
- Pfizer Investigational Site
-
Boden, Sweden, 96131
- Pfizer Investigational Site
-
Degeberga, Sweden, 29731
- Pfizer Investigational Site
-
Gothenburg, Sweden, 40014
- Pfizer Investigational Site
-
Malmoe, Sweden, 21120
- Pfizer Investigational Site
-
Umea, Sweden, 90736
- Pfizer Investigational Site
-
Uppsala, Sweden, 75185
- Pfizer Investigational Site
-
-
-
-
Alabama
-
Mobile, Alabama, United States, 36608
- Pfizer Investigational Site
-
-
Arizona
-
Mesa, Arizona, United States, 85213
- Pfizer Investigational Site
-
Mesa, Arizona, United States, 85203
- Pfizer Investigational Site
-
-
California
-
Fountain Valley, California, United States, 92708
- Pfizer Investigational Site
-
-
Colorado
-
Denver, Colorado, United States, 80262
- Pfizer Investigational Site
-
-
Connecticut
-
Waterbury, Connecticut, United States, 06708
- Pfizer Investigational Site
-
-
Florida
-
Clearwater, Florida, United States, 33761
- Pfizer Investigational Site
-
Coral Gables, Florida, United States, 33134
- Pfizer Investigational Site
-
Jacksonville, Florida, United States, 32216
- Pfizer Investigational Site
-
Pinellas Park, Florida, United States, 33781
- Pfizer Investigational Site
-
Tampa, Florida, United States, 33614
- Pfizer Investigational Site
-
-
Georgia
-
Atlanta, Georgia, United States, 30328
- Pfizer Investigational Site
-
Atlanta, Georgia, United States, 30305
- Pfizer Investigational Site
-
Stockbridge, Georgia, United States, 30328
- Pfizer Investigational Site
-
-
Kansas
-
Shawnee Mission, Kansas, United States, 66128
- Pfizer Investigational Site
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536
- Pfizer Investigational Site
-
-
Maryland
-
Baltimore, Maryland, United States, 21209
- Pfizer Investigational Site
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55417
- Pfizer Investigational Site
-
Rochester, Minnesota, United States, 55905
- Pfizer Investigational Site
-
-
Missouri
-
St. Louis, Missouri, United States, 63141
- Pfizer Investigational Site
-
St. Louis, Missouri, United States, 63104
- Pfizer Investigational Site
-
-
Montana
-
Butte, Montana, United States, 59701
- Pfizer Investigational Site
-
-
Nevada
-
Las Vegas, Nevada, United States, 89146
- Pfizer Investigational Site
-
-
New York
-
Rochester, New York, United States, 14642
- Pfizer Investigational Site
-
-
North Carolina
-
Cary, North Carolina, United States, 27511
- Pfizer Investigational Site
-
Charlotte, North Carolina, United States, 28209
- Pfizer Investigational Site
-
Durham, North Carolina, United States, 27710
- Pfizer Investigational Site
-
Durham, North Carolina, United States, 27705
- Pfizer Investigational Site
-
Hickory, North Carolina, United States, 28601
- Pfizer Investigational Site
-
Raleigh, North Carolina, United States, 27612
- Pfizer Investigational Site
-
Salisbury, North Carolina, United States, 28144
- Pfizer Investigational Site
-
Winston-Salem, North Carolina, United States, 27103
- Pfizer Investigational Site
-
-
North Dakota
-
Fargo, North Dakota, United States, 58103
- Pfizer Investigational Site
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Pfizer Investigational Site
-
Cincinnati, Ohio, United States, 45236
- Pfizer Investigational Site
-
Cleveland, Ohio, United States, 44195
- Pfizer Investigational Site
-
-
Oregon
-
Corvallis, Oregon, United States, 97330
- Pfizer Investigational Site
-
Eugene, Oregon, United States, 97401
- Pfizer Investigational Site
-
-
Pennsylvania
-
Carnegie, Pennsylvania, United States, 15106
- Pfizer Investigational Site
-
Downington, Pennsylvania, United States, 19335
- Pfizer Investigational Site
-
Grove City, Pennsylvania, United States, 16127
- Pfizer Investigational Site
-
Penndel, Pennsylvania, United States, 19047
- Pfizer Investigational Site
-
Pittsburgh, Pennsylvania, United States, 15241
- Pfizer Investigational Site
-
Upper St. Clair, Pennsylvania, United States, 15241
- Pfizer Investigational Site
-
-
South Carolina
-
Greer, South Carolina, United States, 29651
- Pfizer Investigational Site
-
Mt. Pleasant, South Carolina, United States, 29464
- Pfizer Investigational Site
-
-
Tennessee
-
Bristol, Tennessee, United States, 37620
- Pfizer Investigational Site
-
Nashville, Tennessee, United States, 37232
- Pfizer Investigational Site
-
-
Texas
-
Austin, Texas, United States, 78705
- Pfizer Investigational Site
-
-
Virginia
-
Norfolk, Virginia, United States, 23507
- Pfizer Investigational Site
-
-
Washington
-
Seattle, Washington, United States, 998101
- Pfizer Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or Female aged 70 years or older.
- Documented vaccination with 1 dose of 23vPS at least 5 years previous.
- Healthy.
Exclusion Criteria:
- Receipt of more than one dose of 23vPS prior to enrollment.
- History of severe adverse reaction to a vaccine.
- Immunodeficiency.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 1
Receives 13vPnC at year 0 and 13vPnC at year 1
|
0.5-mL dose 13vPnC will be administered into the deltoid muscle at year 0 and year 1
|
|
Active Comparator: 2
Receives 23vPS at year 0 and 13vPnC at year 1
|
0.5-mL dose 23vPS will be administered into the deltoid muscle at year 0 and 0.5-mL dose 13vPnC will be administered into the deltoid muscle at year 1
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC Relative to 23vPS (Vax 1 / Year 0)
Time Frame: 1 month after Vax 1 / Year 0
|
Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assays for the 12 common serotypes (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F).
Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.
|
1 month after Vax 1 / Year 0
|
|
Percentage of Participants Achieving a ≥ 4-fold Rise for Serotype 6A OPA Titer for 13vPnC Relative to 23vPS (Vax 1 / Year 0)
Time Frame: Baseline, 1 month after Vax 1 / Year 0
|
OPA titer for the 6A serotype measured for at least a 4-fold increase from the prevaccination to postvaccination blood sample collection.
Exact 2-sided CI (Clopper and Pearson) based upon the observed percentage of participants.
|
Baseline, 1 month after Vax 1 / Year 0
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pneumococcal OPA Geometric Mean Titer (GMT) for Serotype 6A for 13vPnC Relative to 23vPS (Vax 1 / Year 0)
Time Frame: 1 month after Vax 1 / Year 0
|
Antibody geometric mean titer as measured by OPA assay for the 6A pneumococcal serotype.
Confidence intervals for the GMT are back transformation of a CI based on the Student t distribution for the mean logarithm of the titer.
|
1 month after Vax 1 / Year 0
|
|
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 13 Serotypes for 13vPnC / 13vPnC (Vax 2 / Year 1) Relative to 13vPnC (Vax 1 / Year 0)
Time Frame: 1 month after Vax 1 / Year 0, 1 month after Vax 2 / Year 1
|
Antibody geometric mean titers as measured by OPA assays for the 13 serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F).
Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.
|
1 month after Vax 1 / Year 0, 1 month after Vax 2 / Year 1
|
|
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC / 13vPnC (Vax 2 / Year 1) Relative to 23vPS (Vax 1 / Year 0)
Time Frame: 1 month after Vax 1 / Year 0, 1 month after Vax 2 / Year 1
|
Antibody geometric mean titers as measured by OPA assays for the 12 common serotypes (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F).
Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.
|
1 month after Vax 1 / Year 0, 1 month after Vax 2 / Year 1
|
|
Pneumococcal OPA Geometric Mean Titer (GMT) for Serotype 6A for 13vPnC / 13vPnC (Vax 2 / Year 1) Relative to 23vPS (Vax 1 / Year 0)
Time Frame: 1 month after Vax 1 / Year 0, 1 month after Vax 2 / Year 1
|
Antibody geometric mean titer as measured by OPA assay for the 6A serotype.
Confidence intervals (CI) for the GMT are back transformations of a CI based on the Student t distribution for the mean logarithm of the titer.
|
1 month after Vax 1 / Year 0, 1 month after Vax 2 / Year 1
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC and 23vPS (Vax 1 / Year 0)
Time Frame: Days 1 through 14 / Year 0
|
Local reactions reported in electronic diary.
Redness and swelling scaled as Any (redness or swelling present); Mild (2.5 centimeters [cm] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (>10.0 cm).
Pain scaled as Any (pain present); Mild (awareness of symptom, easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, inability to do usual activity).
Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move above head, able to move above shoulder); Severe (unable to move above shoulder)
|
Days 1 through 14 / Year 0
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Time Frame: Days 1 through 14 / Year 0, Days 1 through 14 / Year 1
|
Local reactions reported in electronic diary.
Redness and swelling scaled as Any (redness or swelling present); Mild (2.5 centimeters [cm] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (>10.0 cm).
Pain scaled as Any (pain present); Mild (awareness of symptom, easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, inability to do usual activity).
Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move above head, able to move above shoulder); Severe (unable to move above shoulder)
|
Days 1 through 14 / Year 0, Days 1 through 14 / Year 1
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 23vPS (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Time Frame: Days 1 through 14 / Year 0, Days 1 through 14 / Year 1
|
Local reactions reported in electronic diary.
Redness and swelling scaled as Any (redness or swelling present); Mild (2.5 centimeters [cm] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (>10.0 cm).
Pain scaled as Any (pain present); Mild (awareness of symptom, easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, inability to do usual activity).
Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move above head, able to move above shoulder); Severe (unable to move above shoulder)
|
Days 1 through 14 / Year 0, Days 1 through 14 / Year 1
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2 / Year 1 )
Time Frame: Days 1 through 14 / Year 1
|
Local reactions reported in electronic diary.
Redness and swelling scaled as Any (redness or swelling present); Mild (2.5 centimeters [cm] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (>10.0 cm).
Pain scaled as Any (pain present); Mild (awareness of symptom, easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, inability to do usual activity).
Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move above head, able to move above shoulder); Severe (unable to move above shoulder)
|
Days 1 through 14 / Year 1
|
|
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 23vPS / 13vPnC (Vax 2 / Year 1)
Time Frame: Days 1 through 14 / Year 0, Days 1 through 14 / Year 1
|
Local reactions reported in electronic diary.
Redness and swelling scaled as Any (redness or swelling present); Mild (2.5 centimeters [cm] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (>10.0 cm).
Pain scaled as Any (pain present); Mild (awareness of symptom, easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, inability to do usual activity).
Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move above head, able to move above shoulder); Severe (unable to move above shoulder)
|
Days 1 through 14 / Year 0, Days 1 through 14 / Year 1
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC and 23vPS (Vax 1 / Year 0)
Time Frame: Days 1 through 14 / Year 0
|
Systemic events reported using electronic diary.
Fever scaled as Any (≥38 degrees Celsius [C]); Mild (≥38 but <38.5 degrees C); Moderate (≥38.5 but <39 degrees C); Severe (≥39 but ≤40 degrees C); Potentially life-threatening (>40 degrees C).
Other systemic events include Fatigue, Headache, Chills, Rash, Vomiting, Decreased appetite, New generalized muscle pain (New muscle pain), Aggravated generalized muscle pain (Aggravated muscle pain), New generalized joint pain (New joint pain), and Aggravated generalized joint pain (Aggravated joint pain).
|
Days 1 through 14 / Year 0
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Time Frame: Days 1 through 14 / Year 0, Days 1 through 14 / Year 1
|
Systemic events reported using electronic diary.
Fever scaled as Any (≥38 degrees Celsius [C]); Mild (≥38 but <38.5 degrees C); Moderate (≥38.5 but <39 degrees C); Severe (≥39 but ≤40 degrees C); Potentially life-threatening (>40 degrees C).
Other systemic events include Fatigue, Headache, Chills, Rash, Vomiting, Decreased appetite, New generalized muscle pain (New muscle pain), Aggravated generalized muscle pain (Aggravated muscle pain), New generalized joint pain (New joint pain), and Aggravated generalized joint pain (Aggravated joint pain).
|
Days 1 through 14 / Year 0, Days 1 through 14 / Year 1
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 23vPS (Vax 1 / Year 0) and 13vPnC / 13vPnC (Vax 2 / Year 1)
Time Frame: Days 1 through 14 / Year 0, Days 1 through 14 / Year 1
|
Systemic events reported using electronic diary.
Fever scaled as Any (≥38 degrees Celsius [C]); Mild (≥38 but <38.5 degrees C); Moderate (≥38.5 but <39 degrees C); Severe (≥39 but ≤40 degrees C); Potentially life-threatening (>40 degrees C).
Other systemic events include Fatigue, Headache, Chills, Rash, Vomiting, Decreased appetite, New generalized muscle pain (New muscle pain), Aggravated generalized muscle pain (Aggravated muscle pain), New generalized joint pain (New joint pain), and Aggravated generalized joint pain (Aggravated joint pain).
|
Days 1 through 14 / Year 0, Days 1 through 14 / Year 1
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC / 13vPnC and 23vPS / 13vPnC (Vax 2 / Year 1)
Time Frame: Days 1 through 14 / Year 1
|
Systemic events reported using electronic diary.
Fever scaled as Any (≥38 degrees Celsius [C]); Mild (≥38 but <38.5 degrees C); Moderate (≥38.5 but <39 degrees C); Severe (≥39 but ≤40 degrees C); Potentially life-threatening (>40 degrees C).
Other systemic events include Fatigue, Headache, Chills, Rash, Vomiting, Decreased appetite, New generalized muscle pain (New muscle pain), Aggravated generalized muscle pain (Aggravated muscle pain), New generalized joint pain (New joint pain), and Aggravated generalized joint pain (Aggravated joint pain).
|
Days 1 through 14 / Year 1
|
|
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for 13vPnC (Vax / Year 0) and 23vPS / 13vPnC (Vax 2 / Year 1)
Time Frame: Days 1 through 14 / Year 0, Days 1 through 14 / Year 1
|
Systemic events reported using electronic diary.
Fever scaled as Any (≥38 degrees Celsius [C]); Mild (≥38 but <38.5 degrees C); Moderate (≥38.5 but <39 degrees C); Severe (≥39 but ≤40 degrees C); Potentially life-threatening (>40 degrees C).
Other systemic events include Fatigue, Headache, Chills, Rash, Vomiting, Decreased appetite, New generalized muscle pain (New muscle pain), Aggravated generalized muscle pain (Aggravated muscle pain), New generalized joint pain (New joint pain), and Aggravated generalized joint pain (Aggravated joint pain).
|
Days 1 through 14 / Year 0, Days 1 through 14 / Year 1
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 6115A1-3005
- B1851024
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.